Najat Khan - 15 May 2025 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Signature
/s/ Kyle Nelson, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
15 May 2025
Net transactions value
-$16,133
Form type
4
Filing time
19 May 2025, 16:44:24 UTC
Previous filing
05 Feb 2025
Next filing
19 Aug 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Khan Najat Chief R&D Commercial Officer, Director 41 S. RIO GRANDE STREET, SALT LAKE CITY /s/ Kyle Nelson, attorney-in-fact 19 May 2025 0002020969

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Tax liability $16,133 -3,796 -0.53% $4.25 708,585 15 May 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RXRX Stock Option (Right to Buy) 420,226 15 May 2025 Class A Common Stock 0 $7.25 Direct F2
holding RXRX Stock Option (Right to Buy) 993,944 15 May 2025 Class A Common Stock 0 $7.34 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F2 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F3 This option vests as to one fourth (1/4th) of the shares subject to the option on July 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter subject to Reporting Person's continued service to the Issuer through each such vesting date.